AP2014007400A0 - 4-Piperidinyl compounds for use as tankyrase inhibitors - Google Patents

4-Piperidinyl compounds for use as tankyrase inhibitors

Info

Publication number
AP2014007400A0
AP2014007400A0 AP2014007400A AP2014007400A AP2014007400A0 AP 2014007400 A0 AP2014007400 A0 AP 2014007400A0 AP 2014007400 A AP2014007400 A AP 2014007400A AP 2014007400 A AP2014007400 A AP 2014007400A AP 2014007400 A0 AP2014007400 A0 AP 2014007400A0
Authority
AP
ARIPO
Prior art keywords
piperidinyl compounds
tankyrase inhibitors
tankyrase
inhibitors
piperidinyl
Prior art date
Application number
AP2014007400A
Other languages
English (en)
Inventor
Christine Hiu-Tung Chen
Lucian V Dipietro
Jianme Fan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AP2014007400A0 publication Critical patent/AP2014007400A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AP2014007400A 2011-07-13 2012-07-13 4-Piperidinyl compounds for use as tankyrase inhibitors AP2014007400A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161507321P 2011-07-13 2011-07-13
PCT/IB2012/053613 WO2013008217A1 (fr) 2011-07-13 2012-07-13 Composés de 4-pipéridinyle utiles comme inhibiteurs de la tankyrase

Publications (1)

Publication Number Publication Date
AP2014007400A0 true AP2014007400A0 (en) 2014-01-31

Family

ID=46604017

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007400A AP2014007400A0 (en) 2011-07-13 2012-07-13 4-Piperidinyl compounds for use as tankyrase inhibitors

Country Status (21)

Country Link
US (2) USRE46942E1 (fr)
EP (1) EP2731940B1 (fr)
JP (1) JP5957077B2 (fr)
KR (1) KR20140051944A (fr)
CN (1) CN103797006B (fr)
AP (1) AP2014007400A0 (fr)
AU (1) AU2012282076A1 (fr)
BR (1) BR112014000792A2 (fr)
CA (1) CA2841932A1 (fr)
CO (1) CO6880065A2 (fr)
CR (1) CR20140071A (fr)
DO (1) DOP2014000012A (fr)
EA (1) EA201490272A1 (fr)
ES (1) ES2548513T3 (fr)
IL (1) IL230430A0 (fr)
MA (1) MA35342B1 (fr)
MX (1) MX2014000536A (fr)
PH (1) PH12014500126A1 (fr)
TN (1) TN2014000016A1 (fr)
WO (1) WO2013008217A1 (fr)
ZA (1) ZA201400374B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181266B2 (en) * 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
EP2822656B1 (fr) 2012-03-07 2016-10-19 Institute of Cancer Research: Royal Cancer Hospital (The) Composés 3-aryl -5-substitué-isoquinolin -1-one et leur utilisation thérapeutique
EP2970121B1 (fr) * 2013-03-15 2017-12-13 Araxes Pharma LLC Inhibiteurs covalents de k-ras g12c
PT3030554T (pt) * 2013-08-07 2018-05-28 Merck Patent Gmbh Derivados de ureia de piperidina
US9611223B2 (en) 2013-09-11 2017-04-04 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
CN105793264B (zh) * 2014-03-10 2017-09-01 四川海思科制药有限公司 取代的二氢苯并呋喃‑哌啶‑甲酮衍生物、其制备及用途
EP3140295B1 (fr) 2014-05-07 2018-09-12 Merck Patent GmbH Dérivés hétérocyclyl-butanamides
KR101739003B1 (ko) 2014-07-11 2017-05-23 에스티팜 주식회사 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
WO2016006975A2 (fr) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
WO2016006974A2 (fr) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation
KR20160007347A (ko) 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
CN108137556B (zh) * 2015-11-02 2021-07-30 默克专利股份公司 1,4-二羰基-哌啶基衍生物
KR101777475B1 (ko) * 2015-12-08 2017-09-11 에스티팜 주식회사 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
EP3394056B1 (fr) 2015-12-22 2021-04-14 Shy Therapeutics LLC Composés pour le traitement du cancer et de maladies inflammatoires
WO2017156350A1 (fr) 2016-03-09 2017-09-14 K-Gen, Inc. Méthodes de traitement du cancer
CA3066939A1 (fr) 2017-06-21 2018-12-27 SHY Therapeutics LLC Composes interagissant avec la superfamille ras destines a etre utilises dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques
EP3891136B1 (fr) 2018-12-03 2023-07-19 Merck Patent GmbH 4-hétéroarylcarbonyl-n-(phényle ou hétéroaryl) pipéridine-1-carboxamides servant d'inhibiteurs de tankyrases
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2021030711A1 (fr) * 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Composés d'alcynyle quinazoline
US20240041859A1 (en) * 2020-12-03 2024-02-08 Washington University Methods of treating and preventing kidney disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
AU2004200A (en) 1999-01-14 2000-08-01 Meiji Seika Kaisha Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
US6710058B2 (en) * 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10056312A1 (de) 2000-11-14 2002-05-16 Bayer Ag Substituierte Amidoalkyluracile und ihre Verwendung
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
JP4391825B2 (ja) 2001-12-06 2009-12-24 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
DE10201240A1 (de) 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
PL372171A1 (en) 2002-02-19 2005-07-11 Ono Pharmaceutical Co, Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
EP1646615B1 (fr) 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Derives de pyrimidne utilises en tant que modulateurs de transporteurs de cassette de liaison a l'atp
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
JP2007513154A (ja) 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
GB0405101D0 (en) * 2004-03-06 2004-04-07 Astrazeneca Ab Compounds
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
KR101286969B1 (ko) 2004-06-30 2013-07-23 얀센 파마슈티카 엔.브이. Parp 저해제로서의 퀴나졸리논 유도체
KR20170001725A (ko) 2004-09-02 2017-01-04 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ATE474829T1 (de) 2005-06-27 2010-08-15 Amgen Inc Entzündungshemmende arylnitrilverbindungen
PL2021337T3 (pl) * 2006-04-25 2010-06-30 Lilly Co Eli Inhibitory dehydrogenazy 11-beta-hydroksysteroidowej typu 1
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
CA2699202C (fr) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinaisons de composes inhibiteurs des phosphoinositide 3-kinases et agents chimiotherapeutiques, et leurs procedes d'utilisation
EP2214675B1 (fr) 2007-10-25 2013-11-20 Genentech, Inc. Procédé de préparation de composés de thiénopyrimidine
US20100267626A1 (en) 2007-11-05 2010-10-21 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
KR101179753B1 (ko) 2007-11-06 2012-09-04 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
RU2490260C2 (ru) 2008-03-27 2013-08-20 Янссен Фармацевтика Нв Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибиторов parp и ингибиторов полимеризации тубулина
US9181266B2 (en) * 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors

Also Published As

Publication number Publication date
ES2548513T3 (es) 2015-10-19
USRE46942E1 (en) 2018-07-10
JP5957077B2 (ja) 2016-07-27
JP2014522855A (ja) 2014-09-08
CN103797006A (zh) 2014-05-14
CR20140071A (es) 2014-10-16
AU2012282076A1 (en) 2014-02-27
KR20140051944A (ko) 2014-05-02
US9163003B2 (en) 2015-10-20
EA201490272A1 (ru) 2014-05-30
MA35342B1 (fr) 2014-08-01
MX2014000536A (es) 2014-12-05
PH12014500126A1 (en) 2014-02-24
EP2731940A1 (fr) 2014-05-21
CO6880065A2 (es) 2014-02-28
CA2841932A1 (fr) 2013-01-17
NZ620426A (en) 2015-08-28
IL230430A0 (en) 2014-03-31
DOP2014000012A (es) 2014-07-31
US20150126513A1 (en) 2015-05-07
WO2013008217A1 (fr) 2013-01-17
BR112014000792A2 (pt) 2017-10-31
EP2731940B1 (fr) 2015-08-19
ZA201400374B (en) 2014-10-29
CN103797006B (zh) 2016-01-27
TN2014000016A1 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
IL273079B (en) Heterocycloamines as pi3k inhibitors
ZA201400374B (en) 4-piperidinyl compounds for use as tankyrase inhibitors
ZA201400232B (en) Metalloenzyme inhibitor compounds
ZA201305612B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
EP2723730A4 (fr) Composés inhibiteurs de métalloenzymes
IL228103A0 (en) Amino-quinolines as kinase inhibitors
ZA201306997B (en) Triazolopyridine compounds as pim kinase inhibitors
HUE037899T2 (hu) Metalloenzim inhibitor vegyületek
IL231403A0 (en) Thiazolopyridine compounds as a10pde inhibitors
EP2751117A4 (fr) Composés inhibiteurs de métalloenzyme
HK1195060A (en) 4 - piperidinyl compounds for use as tankyrase inhibitors